Tiaki Therapeutics is developing first-in-class therapeutics that target microglia, the immune cells of the brain, to address inflammatory-driven CNS disorders and protect cognitive function. The company has developed a proprietary systems biology platform that preserves the complex biological interactions of brain cells and models the specific transcriptomic signature of neuroinflammation in dementia patients. This discovery engine recapitulates the fully integrated cellular communication that is dysregulated in CNS disease, and facilitates identification of novel therapeutic targets and biomarkers. Tiaki’s near-term focus is on therapeutics that counteract the neuroinflammation associated with Alzheimer’s disease.